Voltage-activated calcium channels: Targets of antiepileptic drug therapy?

Epilepsia

Volumn 38, Issue 9, 1997, Pages 959-965

  Stefani, Alessandro ^a,b   Spadoni, Francesca ^b   Bernardi, Giorgio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antiepileptic drugs; Calcium conductances; Neuronal hyperexcitability; Neuroprotective agents; Patch clamp

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 METHYL 1,2 DIPHENYLETHYLAMINE; 2,4 DIAMINO 5 (2,3,5 TRICHLOROPHENYL)PYRIMIDINE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 [2 (1H TETRAZOL 5 YL)ETHYL]DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DEXTRORPHAN; ELIPRODIL; FELBAMATE; FLUNARIZINE; FPL 13950; GYKI 53566; IFENPRODIL; LAMOTRIGINE; LICARBAZEPINE; LIFARIZINE; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; NIFEDIPINE; OXCARBAZEPINE; SIPATRIGINE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CELL; CALCIUM CONDUCTANCE; CALCIUM CURRENT; CYTOTOXICITY; DEGENERATIVE DISEASE; ION CONDUCTANCE; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; PATCH CLAMP; PRIORITY JOURNAL; SODIUM CURRENT; STRIATE CORTEX;

ANIMALS; ANTICONVULSANTS; CALCIUM CHANNELS; CARBAMAZEPINE; DRUG DESIGN; EPILEPSY; HUMANS; MICE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PROPYLENE GLYCOLS; RATS; TRIAZINES;

EID: 0030848858     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01477.x     Document Type: Article

References (103)

1. Dichter MA, Ayala GF. Cellular mechanisms of epilepsy: a status report. Science 1987;237:157-64.
2. Avoli M, Drapeau C, Perreault P, et al. Epileptiform activity induced by low chloride medium in the CA1 subfield of the hippocampal slice. J Neurophysiol 1990;6:1747-57.
3. Macdonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994;35:S41-50.
4. Meldrum BS. Epilepsy and gamma-aminobutyric acid-mediated inhibition. Int Rev Neurobiol 1981;26:207-17.
5. Shachter SC. Review of the mechanisms of action of antiepileptic drugs. CNS Drugs 1995;4:469-77.
6. DeLorenzo RJ. A molecular approach to the calcium signal in brain: relationship to synaptic modulation and seizure discharge. Adv Neurol 1986;44:435-64.
7. Hamill OP, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
8. Hille B. Ionic channels of excitable membranes. 2nd ed. Sunderland, MA: Sinauer Associates, 1992.
9. Matsuki N, Quandt FN, Ten Elick RE, Yeh JZ. Characterization of the block of the sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 1984;228:523-30.
10. Yaari Y, Selzer ME, Pincus JE. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 1986;20:171-84.
11. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993;612:190-9.
12. + channels in rat hippocampal neurones. Eur J Physiol 1995;430:437-46.
13. Heinemann U, Hamon B. Calcium and epileptogenesis. Exp Brain Res 1986;65:1-10.
14. Aicardi G, Schwartzkroin PA. Suppression of epileptiform burst discharges in CA3 neurons of rat hippocampal slices by the organic calcium channel blocker, verapamil. Exp Brain Res 1990; 81:288-96.
15. Morocutti C, Pierelli F, Sanarelli L, Stefano E, Peppe A, Mattioli GL. Antiepileptic effects of a calcium antagonist (nimodipine) on cefazolin-induced epileptogenic foci in rabbits. Epilepsia 1986; 27:498-503.
16. Bingmann D, Speckmann EJ. Depression of pentylentetrazol-induced epileptiform discharges in CA3 neurons of hippocampal slices by flunarizine and verapamil. In: Speckmann EJ, Schulze H, Walden J, eds. Epilepsy and calcium. Munchen: Urban and Schwarzenberg, 1986:301-17.
17. Czuczwar SJ, Gasior M, Janusz W, Kleinrock Z. Influence of flunarizine, nicardipine, and nimodipine on the anticonvulsant activity of different antiepileptic drugs in mice. Neuropharmacology 1992;31:227-36.
18. Prince DA. Electrophysiology of "epileptic neurons"; spike generation. Electroencephalogr Clin Neurophysiol 1989;26:476-87.
19. Speckmann E-J, Walden J. Antiepileptic effects of organic calcium channel blockers in animal experiments. In: Shwartzkroin PA, ed. Epilepsy: model, mechanisms and concepts. Cambridge: Cambridge University Press, 1981:462-86.
20. Vezzani A, Wu Q, Stasi MA, Angelico P, Samanin R. Effects of various calcium channels blockers on three different models of limbic seizures in rats. Neuropharmacology 1988;27:451-8.
21. Kriegstein AR, Suppes T, Prince DA. Cellular and synaptic physiology and epileptogenesis of developing rat neocortical neurons in vitro. Dev Brain Res 1987;34:161-71.
22. Moshé SL, Ludwig N. Kindling. In: Pedley TA, Meldrum BS, eds. Recent advances in epilepsy 4. Edinburgh: Churchill Livingstone, 1988:21-44.
23. Yamada N, Bilkey DK. Nifedipine has paradoxical effects on the development of kindling but not on kindled seizures in amygdalakindled rats. Neuropharmacology 1991;30:501-7.
24. Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:337-84.
25. 2+ channels: diversity of form and function. Curr Opin Neurobiol 1992;2:247-53.
26. Esplin MS, Abbott JR. Smart ML, Burroughs AF, Frandsen TC, Litzinger MJ. Voltage-sensitive calcium channel development in epileptic DBA/2J mice suggests altered presynaptic fucntion. Epilepsia 1995;35:911-4.
27. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989;25:582-93.
28. Luebke JI, Dunlap K, Turner TJ. Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. Neuron 1993;11:895-902.
29. Takahashi T, Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature 1993;366:156-8.
30. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 1996;19:19-24.
31. Frandsen A, Schousboe A. Excitatory amino acid-mediated cytotoxicity and calcium homeostasis in cultured neurons. J Neurochem 1993;60:1202-11.
32. 2+ influx elicited by glutamate: role in neuronal death. Mol Pharmacol 1989;36:106-12.
33. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989;9:127-40.
34. McLean MJ, MacDonald RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983;227:779-89.
35. Morgan KG, Bryant SH. Pentobarbital: presynaptic effect in the squid giant synapse. Experientia 1977;33:487-8.
36. Weakly JN. Effect of barbiturates on "quantal" synaptic transmission in spinal motor neurones. J Physiol 1969;204:63-77.
37. Gross RA, MacDonald RL. Differential effects of pentobarbitone on calcium current components of mouse sensory neurons in culture. J Physiol 1988;405:187-203.
38. Gundersen CB, Umbach JA, Swartz BE. Barbiturates depress currents through human brain calcium channels studied in Xenopus oocytes. J Pharmacol Exp Ther 1988;247:824-9.
39. Ikemoto Y, Mitsuiye T, Ishizuka S. Reduction of the voltage-dependent calcium current in Aplysia neurons by pentobarbital. Cell Mol Biol 1986;6:293-305.
40. Nishi K, Oyama Y. Accelerating effects of pentobarbitone on the inactivation process of the calcium current in Helix neurones. Br J Pharmacol 1983;79:645-54.
41. - current. J Neurosci 1993;13:3211-21.
42. Sayer RJ, Scwindt PC, Crill WE. High- and low-threshold calcium currents in neurons acutely isolated from rat sensorimotor cortex. Neurosci Lett 1990;120:175-8.
43. Sayer RJ, Brown AM, Schwindt PC, Crill WE. Calcium currents in acutely isolated human neocortical neurons. J Neurophvsiol 1993;69:1596-606.
44. Hasbani M, Pincus J, Lee SH. Diphenylhydantoin and calcium movement in lobster nerves. Arch Neurol 1974;31:250-4.
45. Schirrmacher K, Mayer A, Walden J, Dusing R, Bingmann D. Effects of carbamazepine on action potentials and calcium currents in rat spinal ganglion cells in vitro. Neuropsychobiology 1993;27:176-9.
46. Winkel R, Lux HD. Carbamazepine reduced calcium currents in Helix neurons. Int J Neurosci 1991;32:575.
47. 2+ channel (VSCC) antagonists w-Aga-IVA and w-CTX-MVIIC inhibit spontaneous epileptiform discharges in the rat cortical wedge. Brain Res 1994;643:352-6.
48. + channels: local anesthetics, antiarrhythmics and anticonvulsants. Trends Pharmacol Sci 1987;8:57-64.
49. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497-515.
50. Wakamori M, Kaneda M, Oyama Y, Akaike N. Effects of chlordiazepoxide, chlorpromazine, diazepam, diphenylhydantoin, flunitrazepam and haloperidol on the voltage-dependent sodium current of isolated mammalian brain neurons. Brain Res 1989;494:374-8.
51. Waldmeier PC, Baumann PA, Wicki P, Feldatraurer J-J, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-13.
52. Stefani A, Spadoni F, Bernardi G. Lamotrigine inhibits calcium currents in cortical neurons: functional implications. Eur J Pharmacol 1996;307:113-6.
53. Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995;336:997-1002.
54. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996;277:121-9.
55. Calabresi P, Stefani A, De Murtas M, Pisani A, Sancesario G, Bernardi G. Action of GP47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995;36:990-6.
56. Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mrcuri NB, Bernardi G. A field potential analysis of the effects of lamotrigine, GP 47779 and felbamate in neocortical slices. Neurology 1996;47: 557-62.
57. Stefani A, Pisani A, Mercuri NB, Bernardi G, Calabresi P. Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons. J Neurosci 1994;14:6734-43.
58. Yuen AWC. Lamotrigine: a review of antiepileptic efficacy. Epilepsia 1994;35(suppl 5):S33-6.
59. Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs. Epilepsia 1986;27:27-34.
60. Hansworth WL, Wolf HH, Swinyard EA, White HS. Felbamate modulates glycine receptor function. Epilepsia 1993;34(suppl 2): 92-3.
61. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence of anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993;264:248-52.
62. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acid A receptors. Ann Neurol 1995; 35:229-34.
63. Pisani A, Stefani A, Siniscalchi A, Mercuri NB, Bernardi G, Calabresi P. Electrophysiological actions of felbamate on rat striatal neurons. Br J Pharmacol 1995;116:2053-61.
64. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1991;13:171-82.
65. Giroux C, Scatton B. Ischemic stroke: treatment on the horizon. Eur Neurol 1996;36:61-4.
66. Lipton SA, Rosenberg PA. Excitatory amino acids as a common pathway for neurologic disorders. N Engl J Med 1994;330:613-22.
67. Meldrum BS. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994;44(8):S14-23.
68. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-11.
69. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW 619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;24:1063-7.
70. Meldrum BS, Swan JH, Leach MJ, et al. Reduction of glutamate release and protection against ischemic brain damage by BW 1003C87. Brain Res 1992;593:1-6.
71. Smith SE, Meldrum BS, BChir MB. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995;26:117-22.
72. Smith SK, Lekieffe D, Eisenthal D, Dopson M, Nobbs M. BW 619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Neuroreport 1993;4:1339-42.
73. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 1990;112:348-51.
74. Boxer PA, Cordon JJn, Mann ME, Rodolosi LC, Vartanian MG, Rock DM, Taylor CO, Marcoux FW. Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 1990;21:III47-51.
75. 2+ uptake and neurotransmitter release in vitro. Epilepsia 1987;28:378-82.
76. Hayakawa T, Hamada Y, Maihara T, Hattori H, Mikawa H. Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. Life Sci 1994;54:387-92.
77. Rataud J, Debarnot F, Mary V, Pratt J, Stuzmann J-M. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994;172:19-23.
78. Goldstein A Jr, Wells BA, Keats AS. Increased tolerance to cerebral anoxia by pentobarbital. Arch Int Pharmacodyn 1966;161:138-43.
79. Chronopoulos A, Stafstrom C, Thurber S, Hyde P, Mikati M, Holmes GL. Neuroprotective effect of felbamate after kainic acid-induced status epilepticus. Epilepsia 1993;34(2):359-66.
80. Rogawski MA. The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 1992;44:279-92.
81. Rogawski MA, Porter RG. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-86.
82. 2+ channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-D-aspartate receptor antagonist actions. Br J Pharmacol 1994;113:499-507.
83. Scott RH, Sutton KG, Dolphin AC. Interaction of polyamines with neuronal calcium channels. Trends Neurosci 1993;16:153-60.
84. Gotti B, Duverger D, Bertin J, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents: evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther 1988;247:1211-21.
85. Bannan PE, Graham DI, Lees KR, McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 1994;664:271-5.
86. Choi DW, Peters S, Viseskul V. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 1987;82:713-20.
87. Netzer R, Pflimin P, Trube G. Dextrometorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol 1993;239: 209-16.
88. Palmer GC, Cregan EC, Borrelli AR, et al. Neuroprotective actions of 2-amino-N-(1,2-diphenyl)-acetamide hydrochloride (FPL 13950) in a animal models of hypoxia and global ischemia. J Pharmacol Exp Ther 1995;274:991-1000.
89. Steinberg GK, Saleh J, Kunis D. Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci Lett 1988;89:193-7.
90. Steinberg GK, George CP, DeLaPaz R, Shibata DK, Gross T. Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 1988;19:1112-8.
91. Buchan AM, Lesiuk H, Barnes KA, et al. AMPA antagonist: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993;24:I-148, I-152.
92. Bullock R, Graham DI, Swanson S. McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1994; 14:466-71.
93. LePeillet E, Arvin B, Mocada C. Meldrum BS. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischemia in the rat. J Cereb Blood Flow Metab 1992;12:2-11.
94. Pulsinelli WA, Sarokin A, Buchan A. Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. Prog Brain Res 1993;96:125-35.
95. Xue D, Huang Z-G, Barnes K, Lesiuk HJ, Smith KE, Buchan AM. Delayed treatment with AMPA, but not NMDA, antagonist reduces cortical infarction. J Cereb Blood Flow Metab 1994;14: 251-61.
96. Deshpande JK, Wieloch T. Flunarizine, a calcium entry blocker, ameliorates ischemic brain damage in the rat. Anesthesiology 1986;64:215-24.
97. Myer FB, Tally PW, Anderson RE, et al. Inhibition of electrically induced seizures by a dihydropyridine calcium channel blocker. Brain Res 1986;384:180-3.
98. Tytgat J, Pauwels PJ, Vereecke J, Carmeliet E. Flunarizine inhibits a high-threshold inactivating calcium channel (N-type) in isolated hippocampal neurons. Brain Res 1991;549:112-7.
99. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95.
100. Ikonomodou C, Turski L. Excitotoxicity and neurodegenerative diseases. Curr Opin Neurol 1995;8:487-97.
101. Beal MF. Does impairment of energy metabolism result in excitotoxic death in neurodegenerative illnesses? Ann Neurol 1992; 13:119-30.
102. Whetsell WO Jr. Current concepts of excitotoxicity. J Neuropathol Exp Neurol 1996;55:1-13.
103. Wilder BJ. The treatment of epilepsy: an overview of clinical practices. Neurology 1995;45(suppl 2):S7-11.